Vera Therapeutics Gets FDA Accelerated Approval for Trutakna in IgA Kidney Disease

Vera Therapeutics said the U.S. Food and Drug Administration granted accelerated approval for Trutakna to reduce proteinuria, or protein in urine, for adults with primary IgA nephropathy who are at ...

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy July 7, 2026 4:30 PM EDTCompany ParticipantsSean Grant ...
The Manila Times

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...
MedPage Today on MSN

First-in-class drug approved for IgA nephropathy

It has not been established whether atacicept slows kidney function decline long-term, how ...
Healio

FDA approves Trutakna for proteinuria reduction in IgA nephropathy

The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A ...
Yahoo

US FDA's accelerated approval for drugs needs more transparency, says research firm

Add Yahoo as a preferred source to see more of our stories on Google. A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. Picture taken ...